A Tuberculosis Guide for Specialist Physicians

A Tuberculosis Guidefor

Specialist Physicians

2003

Jose A.Caminero Luna

International Union Against Tuberculosis and Lung Disease

68 boulevard Saint Michel, 75006 Paris - France

This publication was made possible thanksto the support of the United States Centersfor Disease Control and Prevention (CDC)

: .,.,.

: .

2007

1: ,(.) 2: (.) 3: (.) 4: (.) 5: ,(.) 6: (.) 7: (.) 8: - (.) 9: (.) 10:(.) 12:(.) 13:(.) 14:(.) 15:(.) 16:(.) 17:(.) 18:(.)

.. , PCR Ak aCip Cp Cs Ctz E Eth H Kn Ofl Pas --Pt R S T Z

, Jose A. Caminero Luna- . , [email protected].

,.

.,,.

.h t t p : / /www. iua t ld . o r g/ fu l l_p i c tu re/en/ f ramese t / f ramese t .

phtml?page=http://www.iuatld.org/full_picture/en/about/divisions/division_publications.phtml

.

, , ,, . , .

(),(),.

()- ..

,.

- (, ) . ..

Dr.Negrin -,.

,

:Drs. JosAlcaide (Barcelona),NievesAltet (Barcelona),VicenteAu-

sina (Barcelona), Mara Jos Bguena (Valencia), Csar Bonilla (Peru),MariaIsolinaCampos(LasPalmasdeGranCanaria),ManuelCasal(Cor-doba),JonCayl(Barcelona),DonaldEnarson(Canada),AntonioLobo(Jerez-Cadiz),PilarLopez-Facal(LasPalmasdeGranCanaria),JoseMariaManterola (Barcelona), JunRuizManzano (Barcelona),PeredeMarch(Barcelona),CarlosMartin(Zaragoza),JuanDomingoPalmero(Argenti-na),MariaJosePena(LasPalmasdeGranCanaria),JoseLuisPerez-Arel-lano(LasPalmasdeGranCanaria),JoseMariaPina(Barcelona),RafaelRey (Madrid),MiguelAngelSalazar (Mexico), JesusSauret (Barcelona),andRafaelVidal(Barcelona).

1 -

,

. 13 (),. , .5 . 30 ,, . , , ..:1.()-,2.-,3. - . .

10 XXI .,

10 11

40 ,.()-1400-13 . - 1 23.-12 0 22 -.

- .(12-)-, . 5- . - .30 ,-.

, ( ) -. . -. - ,.

10. 30 . 1 5.-1145,335 2.3 . 1, 1 .1 22 :, , , , , . 1 1,35,0002222(131000), 1 ( 3 000 ) .1,1. , , , , ( ) 1 214342(.3). - .

. . , . : (- ), . . .

- - .-

12 13

. ,. , , , .- . .

. , . ,, ,, . ,. 0 .. . , ,.

. .- . .

-

-, .- , . - ,, //.,. ( ,),.

- 1-3 .,,,, .. - , , .

, . . . ..

- . , . .

14 15

-.,,, - . - .

2 -

- , - . .- . , .,-., , . . -.1 ( ), ()-.3-525

1 1

. - ..

,.

. , . , , - ,-.

. .,.

, - , , . , . . : 2 , .

.

. , . . -.

, . -.,- .

- . . . - , , . . .

-

1 1

.,. ( ) - . , ( ) .

, . . .

-

- . 1, . - , . 3-5 25 .

- .,,,-..

1-. ..030 . 10 . . .

, , , , - ,,3. .0 , , . , - .-.

200221: 5, 3, , , , ,2,,,-1 . .

1. .-.2. .-.-

20 21

3. .4. .5. .. .

.. .. .,

-.. .,.10. ..11. ..12. .13. ..

.-.14. .

.15. ..

.1. ..1. .1. ..

.1. ..

.20. .

.21. ..

.22. ..23. .,,

.24. .25. .2. .

..2. .2. .2. .30. ,,.31. -.32. .33. .34. -.

.35. .. -

3 -

. . Mycobactreium tuberculosis- . ( 4-% ), (-%).

Mycobacterium tuberculisis-

. . Mycobacterium tuberculosis 15,300 20,400 , Mycobacter- . Mycobacteriumtuberculosis . . Mycobacter- (M.ulcerans .) 150 . Mycobacter- .M.tuberculosis, M.bovis, M.africanum, M.microti M.tuberculosisM.bovis.Mycobacter-

22 23

M.bovis .M.tuberculosis . .,M.tuberculisis100-150 . () . .

.

( 40-3) XIX ,..,(130-200) . XVII ,,,, . .

XIX (15), (143-110) ..

. () . ,.

M.tuberculosis-., .,550%25%1. 25-30% .,. . 50.

XVIII . . , , ,.

XIX .,. . , .

24 25

,.XIX,XX

. . . . .

?113201200 . 3%. 1%, .5% .

.II ,. () . . ,(),,( ), ( ),,,,,,.

XIXXX.

. ,. .12 40% , 1% . .

. . (13 ) . . (143),141 . 143 , 144.150-.

.XVIII 4-%.

.

2 2

. .,..

. -%. 12-14% . 30-40 ..

1. AmericanThoracicSociety.Diagnosisandtreatmentofdiseasecausedbynontuberculousmyco-bacteria.AmRevRespirDis.10;142:40-53.

2. BguenaMJ.LaTuberculosisySuHistoria.Barcelona,Spain:FundacinUriach13;12.3. BatesJH,SteadWW.Thehistoryoftuberculosisasaglobalepidemic.MedClinNorthAm.

13;:1205-121.4. DanielTM.Theoriginsandpre-colonialepidemiologyoftuberculosisintheAmericas:canwe

figurethemout?IntJTubercLungDis.2000;4:35-400.5. FarerLS.Thecurrentstatusoftuberculosiscontrolefforts.AmRevRespirDis.1;134:402-

40.. HaasF,HaasSS.TheoriginsofMycobacteriumtuberculosisandthenotionofitscontagious-

ness.In:RomWN,GaraySM,eds.Tuberculosis.Boston,Massachusetts:Little,BrownandCo;1:3-1.

. HareR.Theantiquityofdiseasescausedbybacteriaandviruses.Areviewoftheproblemfromabacteriologistspointofview.In:BrothwellD,SandisonAT,eds.DiseasesinAntiquity.ASurveyoftheDiseases,InjuriesandSurgeryofEarlyPopulations.Springfield,Illinois:CharlesC.Thomas;1:115-131.

. HaymanJ.Mycobacteriumulcerans:aninfectionfromJurassictime?Lancet.14;2:1015-101.. HerzogH.Historyoftuberculosis.Respiration.1;5:5-15.10. KapurV,WhittamTS,MusserJM.IsMycobacteriumtuberculosis15000yearsold?JInfectDis.

14;10:134-134.11. MedinaV,SauretJ,CamineroJA.Enfermedadesproducidaspormicobacteriasambientales.

MedClin(Barc).1;113:21-30.12. OBrienRJ,GeiterLJ,SniderDE.Theepidemiologyofnontuberculousmycobacterialdiseases

intheUnitedStates.Resultsfromanationalsurvey.AmRevRespirDis.1;135:100-1014.13. SauretJ.LaTuberculosisaTravsdelaHistoria.Madrid,Spain:RAYMAServicioEditorialSL;

10.14. SteadWW,EisenachKD,CaveMD,etal.WhendidMycobacteriumtuberculosisinfectionfirst

occurinthenewworld?Animportantquestionwithpublichealthimplications.AmJRespirCritCareMed.15;151:12-12.

15. StybloK.Recentadvancesinepidemiologicalresearchintuberculosis.AdvTubercRes.10;20:1-3.

1. TimpeA,RunyonEH.Therelationshipofatypicalacid-fastbacteriatohumandisease.Apreliminaryreport.JLabClinMed.154;44:202-20.

1. YoungDB.Blueprintforthewhiteplague.Nature.1;33:515-51.

2 2

4 -

: , . ( ), ( /),(),().

,:,- ( ).-1,41,000 (141/100,000), 3,24,000 (2/100,000 ). 0 23.

.(4-%),(-%) . ,- , ,-,.

. ,,, , .

..

()M.tuberculosis- M.bovis- . . .,,,. .

:1.2.3.4.

Actinomycetales- Mycobacteriaceae- . M.tuberculosis,M.bovis,M.africanum,M.microtiM. tuberculosis complex - . M.tuberculosis .M.bovis-.M.bovis M.africanum .M.microti() . Mycobacteriaceae- 0 ..mycobacterimycobacteri.

, , ,.

, , -,,..

30 31

. Nocar-dia,..,. . ..

(0),.. ..:, . (H .40)100140..,1424.

()..

,,,.

( ) . , .:

.

M.tuberculosis-,M.bovis- ( , , )M.tuberculosis-. .

.... .

. , , , . 10 . 5-10 . 1-5 1-5. . 10-200 . ., . . .

.M.bovis-

32 33

. M.avium- - .,,, ( 200-300 ) ..

:1. . ,

.

2. ,..

3. ..

4. . 50 . 2.

5. :), , , ) , ),.

:

5- , 5-0 .-14.

(0-0%).

,.

. .,1000.Relativerisk.2-.

2.

Relativerisk

- 50-100 2-3 1-3 -34, 1 10-15 4-15 2-14 2-12 5 2-4 2-4 2-4 1

1. AmericanThoracicSociety.CentersforDiseaseControlandPrevention.Targetedtuberculin

testingandtreatmentoflatenttuberculosisinfection.AmJRespirCritCareMed.2000;11(sup-pl):S221-S24.

2. CamineroJA,MedinaMV,RodrguezdeCastroF,CabreraP.Tuberculosisyotrasmicobac-teriosis.In:CamineroJA,FernndezFauL,eds.ManualdeNeumologayCirugaTorcia.Madrid,Spain:EDIMPSA;1.

3. ClancyL.Transmisibilidaddelatuberculosis.BolUnInternTubercEnfRespir.10;5:-.4. HobbyGL,HolmanAP,IsemanMD,JonesJM.Enumerationoftuberclebacilliinsputumof

patientswithpulmonarytuberculosis.AntimicrobAgentsChemother.13;4:4-104.5. RiederHL,CauthenGM,SniderDE.EpidemiologyoftuberculosisinUnitedStates.Epidemiol

Rev.1;11:-.. RiederHL.EpidemiologicBasisofTuberculosisControl.Paris,France:InternationalUnion

AgainstTuberculosisandLungDisease;1.30. RileyRL,MillsCC,OGradyF,SultanLU,WittsadtF,ShivpuriDN.Infectiousnessofairina

tuberculosisward.AmRevRespirDis.12;5:511-525.

:, .

34 35

. . ,. . .( ). . .

3 : , . . . . ( ), ( ) . , 2 . . , . .

( ) ()100,000.

, (). . . . ..- , , ..

1. ArnadottirTh,RiederHL,TrbucqA,WaalerHTh.Directivaspararealizarencuestastuber-culnicasenpasesdealtaprevalencia.Paris,France:InternationalUnionAgainstTuberculosisandLungDisease;1.32

2. CamineroJA,MedinaMV,RodrguezdeCastroF,CabreraP.Tuberculosisyotrasmycobac-teriosis.In:CamineroJA,FernndezFauL,eds.ManualdeNeumologayCirugaTorcia.Madrid,Spain:EDIMPSA;1.

3. RiederHL.EpidemiologicBasisofTuberculosisControl.Paris,France:InternationalUnionAgainstTuberculosisandLungDisease;1.

4. StybloK.Relacinentreelriesgodeinfeccintuberculosayriesgodedesarrollarunatuberculosiscontagiosa.BolUninIntTubercEnfRespir.15;0:11-11.

. 5% % .

3 3

.-13,,22,,41,000 ( 141 / 100 000 ), 3,24,000 (2 / 100 000 ) .0%23.

. ... , . .

- 1 3,,22 . 50%-1,41,000(141/100000),3,24,000(2/100000) . ( 1). 1 3%(41%,22% ) 1% %,10%,4%.

. 0% - 23 (3).23 (100,000 ). . 1 1,4,000 .

-.

40,30..

1

.

,

,

1999

3 3

3. 1999 : 23 . : 6, , 2001

/ * 100000

1 14000 103

2 12. 1300000 22

3 20.2 50000 301

4 10. 32000 241

5 12. 30000 1

152.3 2000 314

4.4 234000 33

1 22000 45

3. 1000 123

10 14.1 11000 401

11 50.3 151000 1

12 . 14000 41

13 2.5 123000 0

14 1. 11000 340

15 32. 112000 141

1 0. 000 40

1 1.2 000 1

1 45 000 343

1 21.1 2000 425

20 21. 1000 52

21 11.5 5000 50

22 10. 1000 22

23 25.2 5000 1

:23

30 00000 141

55 4100015

*-

1. CantwellMF,SniderDEJr,CauthenGM,OnoratoIM.EpidemiologyoftuberculosisintheUnitedStates,15through12.JAMA.14;22:535-53.

2. ClancyL,RiederHL,EnarsonDA,SpinaciS.TuberculosiseliminationinthecountriesofEu-ropeandotherindustrializedcountries.EurRespirJ.11;4:12-125.34

3. RaviglioneM,SniderD,KochiA.Globalepidemiologyoftuberculosis.Morbidityandmortalityofaworldwideepidemic.JAMA.15;23:220-22.

4. RaviglioneMC,RiederHL,StybloK,KhomenkoAG,EstevesK,KochiA.TuberculosistrendsinEasternEuropeandformerUSSR.TubercleLungDis.14;5:400-41.

5. WorldHealthOrganization.GlobalTuberculosisControl.WHOReport1.Geneva,Switzer-land:WHO;1.

. WorldHealthOrganization.GlobalTuberculosisControl.WHOReport2001.Geneva,Switzer-land:WHO;2001.

. 20-() 10.,-,M.tuberculosis3. .

. - . .

.40, - , .: 0% 50 5%50-. - . -.

40 41

13 4- 5.:1)2) 3) ( ) 4) 5) ,. ..- . . 1 23%12 - . 2- -.

150 ..1 ( 3) , , , . (-55 ) . (4)(3125),(312-55) .,.,,

2.

-

. D

DR-

-

, T

S-

42 43

3

.

,

,

1998

4

.

,

,

1998

44 45

,.,,.,,.

. ,-.

-

- . - . . ..

1-/- 33. 1.3 .-. 1 2. - - . - 5% .. 1 - 0%(23.3 ) , 20% (. ) ,5%(1.).- . -

,. , - .()- - 201020151.

/- 5%, / 5%- . 10 0%-50-- 5-0% .--.(204)10.

1-.,3CD4+,-. . - .

40-50. . .

4 4

. , .,.

10 . ,.5-10.

, , , , ,20. ,.,, . .

. .30 2 . - 10-2000 . , 23 0%-.

1. CantwellMF,SniderDEJr,CauthenGM,OnoratoIM.EpidemiologyoftuberculosisintheUnitedStates,15through12.JAMA.14;22:535-53.

2. ClancyL,RiederHL,EnarsonDA,SpinaciS.TuberculosiseliminationinthecountriesofEu-ropeandotherindustrializedcountries.EurRespirJ.11;4:12-125.

3. DaviesRPO,TocqueK,BellisMA,RimmingtonT,DaviesPDO.Historicaldeclinesintubercu-losisinEnglandandWales:improvingsocialconditionsornaturalselection?IntJTubercLungDis.1;3:1051-1054.

4. DeCockKM,SoroB,CoulibalyMI,LucasSB.TuberculosisandHIVinfectioninsub-SaharanAfrica.JAMA.12;2:151-15.

5. FauciAS.TheAIDSepidemic.Considerationsforthe21stcentury.NEnglJMed.1;341:104-1050.

. McKennaMT,McCrayE,OnoratoI.TheepidemiologyoftuberculosisamongforeignbornpersonsintheUnitedStates,1to13.NEnglJMed.15;332:101-10.

. MurrayJF.Unprogramamundialcontralatuberculosisemerge:agendadeinvestigacines,incluyendoelimpactodelainfeccinVIH.BolUninIntTubercEnfResp.11;:22-231.

. NarainJP,RaviglioneMC,KochiA.HIV-associatedtuberculosisinthedevelopingcountries:epidemiologyandstrategiesforprevention.TubercleLungDis.12;3:311-321.

. RaviglioneMC,RiederHL,StybloK,KhomenkoAG,EstevesK,KochiA.TuberculosistrendsinEasternEuropeandformerUSSR.TubercleLungDis.14;5:400-41.

10. RaviglioneMC,SudreP,RiederHL,SpinaciS,KochiA.SeculartrendsoftuberculosisinWest-ernEurope.BullWorldHealthOrgan.13;1:2-30.


12. StephensonJ.HIVsoriginstracedto130s.JAMA.2000;23:12.13. StybloK.ImpactodelainfeccinVIHenlaepidemiologamundialdelatuberculosis.Bol

UninIntTubercEnfResp.11;:2-33.14. YanaiH,UthaivoravitW,PnichV,etal.RapidincreaseinHIV-relatedtuberculosis,Chiang

Rai,Thailand,10-14.AIDS.1;10:52-531.

(4-%),(-%). .

XVIII

4 4

. .XVIII, , . ,, . .2020%(2). .. 4-% . .

143 , ..XVIII 150- . -%. . , .

,

- .:- , - , - . . . ,() () . 1%-.

. 5- ( 5% ).

1. BguenaMJ.LaTuberculosisySuHistoria.Barcelona,Spain:FundacinUriach13;12.2. BatesJH,SteadWW.Thehistoryoftuberculosisasaglobalepidemic.MedClinNorthAm.

13;:1205-121.3. HaasF,HaasSS.TheoriginsofMycobacteriumtuberculosisandthenotionofitscontagious-

ness.In:RomWN,GaraySM,eds.Tuberculosis.Boston,Massachusetts:Little,BrownandCo;1:3-1.


5. SauretJ.LaTuberculosisaTravsdelaHistoria.Madrid,Spain:RAYMAServicioEditorialSL;10.

. YoungDB.Blueprintforthewhiteplague.Nature.1;33:515-51.

50 51

5 - ,

.. (4- ) , .

0%- . 5% 5% ().-50-0%.

.

. M.tuberculosis-1,. .

. ,,. . .

. Lurie, Dannenberg Lefford

.Lurie . : (3- ), , . . ,.Lurie,Dannenberg , . Lefford .Lefford ...

. : Rook D10 .

.

. 5%5%.. .

52 53

.. 5 - 10 (Pfluger droplet) .1-5 3 .(,)5- . 1-5 . 10-200 . .: , / ../ . ..

. :..: . . . ..

. ..-, . . ..

..,. ..

. . . ,,,..

: . ., .(delayedhypersensitivity)(caseousnecrosis)

54 55

. ,., , . ..

T ,.. . , ....

. ..

.0%

. 5% 5% ( 5). -50-0%.. (4,2).

. (- , , . ) . arabinomanan- . .

5.

5 5

...

. . .. . .

1. LurieMB.ResistancetoTuberculosis:ExperimentalStudiesinNativeandAcquiredDefensiveMechanisms.Cambridge,Massachusetts:HarvardUniversityPress;14.

2. BhardwajV,ColstonMJ.Theprocessingandpresentationofmycobacterialantigensbyhumanmonocytes.EurJImmunol.1;1:1-.

3. CamineroJ,PenaMJ,Campos-HerreroMI,etal.ExogenousreinfectionoftuberculosisonanEuropeanislandwithamoderateincidenceofdisease.AmJRespirCritCareMed.2001;13:1-20.5

4. DannenbergAM.Immunemechanismsinthepathogenesisofpulmonarytuberculosis.RevInfectDis.1;2(suppl2):S3-S3.

5. EdwardsD,KirkpatrickCH.Theimmunologyofmycobacterialdiseases.AmRevRespirDis.1;134:102-101.

. EllnerJJ,WallisRS.Immunologicaspectsofmycobacterialinfections.RevInfectDis.1;2(suppl2):S455-S45.

. KauffmanSHE.Invitroanalysisofthecellularmechanismsinvolvedinimmunitytotuberculo-sis.RevInfectDis.1;2(suppl2):S44-S454.

. LeffordMJ.Transferofadoptiveimmunitytotuberculosisinmice.InfectImmun.15;11:114-111.

. LowrieDB,AndrewPW.Macrophageantimycobacterialmechanisms.BrMedBull.1;44:24-34.

10. RookGAW.Roleofactivatedmacrophagesintheimmunopathologyoftuberculosis.BrMedBull.1;44:11-23.

11. SkameneE.Geneticcontrolofsusceptibilitytomycobacterialinfections.RevInfectDis.1;2(suppl2):S34-S3.

6 - :

. -(),. . () , , , ,.

(PPD)-RT23 2 , PPD-CD- 5 .PPD-S- 5 . . ,-,-..

, . .(,),(), . .,

5 5

. , .

5. . . ().

. ,, . ,, () . . . ESAT- ()(Enzyme-linkedimmunosorbentassayforgam-mainterferon-ELISPOT).

. .().1010- ,..105( ) , 10

.

. 2- . . . ,. , . . , . ( ) , , . , ,.5-,4-2 . .

.. ( ,,,.),-,-.,.

0 1

6. -RT23- 2 , 72

22

. ( ) ..134 (PPD) . PPD- ..151PPD-,PPD-S.

PPD PPD-S- . PPD . PPD-RT21, PPD-RT23, PPD-CT . - ,PPD-RT23.

0.1 . ( ) PPD- . PPD-S- 5 (TU) . PPD-RT23- PPD-S-2PPD-RT23-2 (PPD-S- 5 TU- ).

. () PPD-S- 5 TU (PPD-).

-10( ), (2G 0.4/12) . . . , .( ). ().

2 3

7.

, . (+,++.) . ,(), . .

PPD-S5TUPPD- - .. 4- ,4-2.

Sokalball-pointpenmethod..

. ...(0). . . . -0(). , ( ), . ,.

. . . ,,(-).:PPD-RT232TU-2_____-.

8. PPD-RT23 2 TU- 72 30 - .

4 5

4- . ..,..(,).

- -

-

25 . (, ) . 50 .()(). ( ) .PPD-, .

- ,,..5. - . - -

-50.-4-.

2-12 . . -12, . : , . () (booster effect, )-10..

4. -

1. - - - :,,, - :,,

,,, - - :(4

),,,, - - - ,,() - - - ,,, - ,2. - (,) - - - (Tween0)3. - - - - 4. - -

-

- , . , .

, . PPD- , . ().

, . ., . ,, , . . . .25 ( ) . ,,,15-.

( ) .

. .

..

, . 5 - . - . , 1-1 - -. -5-,- . , . , - (15)...

positive predictive value (PPV)- . PPV . PPV . , .

5-PPV-.PPV- ( )5( ) .

- .,.

. PPV.

. (Tuberculinconversion)..

.,.

. 2 . ,. .5-.: -12 - . .

- , . PPD

. , . . , -10 . . . , . 55-..,.

. -10 . .

( ) .,,.

. : , . PPV,

0 1

. ,PPV. , - . , . .- , . . ,.

, :1. .

PPV..

2. . . .

3. ..,.(-12, ). .

., . (), ., , . , , .,.: , . .5-%-PPV-.,., , . , ., . ,.

2 3

1. ComstockGW,LivesayVT,WoolpertSF.Theprognosisofapositivetuberculinreactioninchildhoodandadolescents.AmJEpidemiol.14;:131-13.

2. EdwardsLB,AcquavivaFA,LivesayVT.Identificationoftuberculousinfected.Dualtestanddensityofreaction.AmRevRespirDis.13;10:1334-133.

3. LalvaniA,PathanAA,DurkanH,etal.Enhancedcontacttracingandspatialtrackingofmycobacteriumtuberculosisinfectionbyemunerationofantigen-specificcells.Lancet,2001;35:201-2021.

4. LordiGM,ReichmanLB.Tuberculinskintesting.In:Schloesberg,ed.TuberculosisandNon-tuberculosisMycobacterialInfections.4thed.Philadelphia,Pennsylvania:W.B.SaundersCo;1:5-0.

5. MarchP.MicobacteriasnotuberculosasenBarcelona.(I)SensibilizacionescomparativesentretuberculinaRT23consensitinasdeMycobacteriumaviumyscrofulaceum.RevClinEsp.14;15:141-14.

. MenziesD.Interpretationofrepeatedtuberculintests.AmJRespirCritCareMed.1;15:15-21.

. MiretP,PinaJM.LapruebadelatuberculinaenlosvacunadosconBCG.ArchBronconeumol.1;34;421-424.

. PesantiEL.Thenegativetuberculintest.AmJRespirCritCareMed.14;14:1-10.. PinaJM,MartinA,GonsalesP,LopezJL,MiretP.Lapruebadelatuberculina.MedicinaInte-

gral.1;13:330-344.10. AmericanThoracicSociety.Tuberculinskintest.Diagnosticstandardsanclassificationoftuber-

culosisinadultsandchildren.AmIRespirCritcareMed.2000;11:13-135.11. VillarinoM,BrennanMJ,NolanCM,etal.Comparisontestingofcurrent(PPD-S1)and

proposed(PPD-S2)referencetuberculinstandards.AmIRespirCritcareMed.2000;11:11-111.

7 -

. , ( ), ( ), ( ) . (),.

, . . .,. . .

, , .,: . ..

4 5

, . .

. .2-3 . () . . .

. ,: ..,. : , , ..

... 0-5%- .,.,.,.

, (

) , ,,,.15-20%-,.- 50-0%- .

,, , , .

, , .15,,, .

, ,,,.,,.,. .,.

( ) , . , , .

,. , .

, . , 2-3

.(). ( ).-, .

- . .-,(,,,.), , . - .

,..,:-

.

- .

- ,.

- :o ,o (, )

, ,.

- .-

.

, .:-

().- ().50-0

-.- .-

, ().

- (/-) . ,.

- , , .

- ()(), ().

(). - . .,.,.

...

,10-().

> 14-21

3

9: - : .

10: - : ( ). . . , , , .

1. AmericanThoracicSociety.Diagnosticstandardsandclassificationoftuberculosis.AmRevRespirDis.10;142:25-35.

2. CamineroJA,CasalM,AusinaV,PinaJM,SauretJ.NormativaSEPARsobrediagnosticodelatuberculosis.ArchBronconeumol.1;32:5-.

3. CamineroJA,MedinaMV,RodriguezdeCastroF,CabreraP.Tuberculosisyotrasmicobacteri-osis.In:CamineroJA,FernandezFauL.eds.ManualdeNeumologiayCirugiaToracia.Madrid,Spain:EDIMPSA;1.

4. KhanMA,KovnatDM,BachusB,WhitcomsME,BrodyJS,SniderGL.Clinicalandroent-genographicspectrumofpulmonarytuberculosisintheadulst.AmJMed.1;2:31-3.

,.,, . . ,(0.%). . . 3 . . , . . ..

0 1

20 .-,,,., , .( 100%) , -.

. , . . ( - ), , ., , ., .. ( 10) .

., . .

% M.Tubercalosis- ..

- . 4-5 .,,, , , ... (4-5) ,(invitroinvivo)()().

. , . .-.

, , . . :

2 3

1. .

2. ,,.

3. , , ..

4. ( , , ) ,.

5. . .

. . 5%-. 5%- ( 2 10%- ) 100%-.()..

. 3 . .4.,, 3 . ,. . , ..

. , . .. ,

. -10..4-5,...

. : , .

10. .. .,. ,...

11. . , .. , . , . ,

4 5

.12. 3

. . . . . . .

13. ,..

14. - ( , , , ) . .

12 . 10- . , ,. , , . .

.10-

.. .

10- .-, . 10--,.,() , (,).10 . .

.,.

. .

: 1) ,2),3),4).

-, .

. ( 4- ). , ,.,.

- , .,.1000,,10-15 . ..:

() /100(+) 1-/100(++) 10-/100(+++)1-10(50 )(++++)>10(20 )

11: - . , .

. , :1),2),3),4),5). . . 1 - 10,000 . 5,000 . 0.01-50.2001.10050%.

. .- .

. (0-0%), (50-0%),(50% ). . . , -, ,., . .1001%-,2002%-,3003%-.30015-20. . (+++++)(11) . . - . - , . 25-30 .

, . . , Nocardia- , , , . . . - ,.

. .

. -..() . () - . .

,,. . .

. . . (, , , ) . , . , . ,.

. :

1. 1-10.

0 1

2. ..

3.,. ( ) . , ..

.

1. (divisional ca-pacity) . 4-, . .

2. ,.

. , .

, .,, . . . ( ).

.

, ,.

( , , ..) . -,, (10).

,(-, ) (Middlebrook 10 11) . -(12).-, M. haemophilum, M.malmoense, M. genavense,M.avium,,, . 5-10%- .

12. (, ) -

2 3

, ,,.,() . (Bactecsystem),(MB-Septi-Check)..

. , , ( M.bovis- ) () . , 20. , , , . ,(-)..

. % . ,, .

.

. . . ,-.. .

In vitro ()

-, . In vitro , , , - .-()(MiddlebrookH10). (Bactec) . -.

- - 4-5 , (Middlebrook H10 11)2-4,5-.-(),.3-,Bactec12-21.-Bactec3.

4 5

. - . . 1 ..

,., , , - . -.-- 14 .,(5).,,-.-, ,.

, , ( ) ( )- . -- . 4-5 . 2,1,-1,,

1.invitro()invivo()100%-. - .

1. AmericanThoracicSociety.Diagnosticstandardsandclassificationoftuberculosis.AmRevRespirDis.2000;11:13-135.

2. AusinaV,ManterolaJM,PadillaE.Nuevasperspectivaseneldiagnosticotoracia.In:SauretJ,ed.Tuberculosis,VisionActual.Madrid,Spain:AulaMedicaEdiciones;2001:23-5.

3. AusinaV.Actualidadelatuberculosis.Unavisioncriticadelasnuevastecnicasdiagnosticas.EnfInfectMicrobiolClin.12;10:24-254.


5. CamineroJA,MedinaMV,RodriguezdeCastroF,CabreraP.Tuberculosisyotrasmicobacteri-osis.In:CamineroJA,FernandezFauL.eds.ManualdeNeumologiayCirugiaToracia.Madrid,Spain:EDIMPSA;1.

. FargaV.Diagnosticodelatuberculosispulmonar.In:FargaV,ed.Tuberculosis.SantiagodeChile:Edit.Meditteraneo;12:103-11.

. HeubnerRE,GoodRC,TokarsJI.Currentpracticesinmycobacteriology:resultsofasurveyofstatepublichealthlaboratories.JClinMicrobiol.13;31:1-5.

. HopewellPC.Mycobacterialdiseases.In:MurrayJF,NadalJ,eds.TextbookofRespiratoryMedicine.Philadelphia,Pennsylvania:W.B.SaundersCo;1.

. RobertsGD,KonemanEW,KimYK.Mycobacterium.In:BalowsA,ed.ManualofClinicalMicrobiology.5thed.Washington,D.C.:AmericanSocietyofMicrobiology;11:304-33.

10. EnarsonDA,RiederHL,ArnadottirT,TrebucqA.ManejodelaTuberculosis,GuiaparalosPaisesconEscasosEconomicos.5thed.Paris,France:UnionInternacionalContralaTuberculo-sisyEnfermedadesRespiratorias;2000.

11. WolinskyE.Conventionaldiagnosticmethodfortuberculosis.ClinInfectDis.14;1:3-401.

. . . 3- , .

,

.. , . 2 , . , . . .

. ( ..),, . . (13).(14).

13. 72 . ( ).

14. . .

, 3-, . . ():. . . . , - . , 100%-.

( ) (15), ( 1) . , pulmonary consolidation, ( ),

()(), ( ).

15. 42 . .

, ,(1,1)., ( 1), ( 20). () . , ( 22, 23). (24).,

.(25).

16. 7 . . .

17. 36 . . .

100 101

18. 39 . . . .

19. 52 . . .

20. 18 . .

21. , 49 . .

102 103

22. 24 . .

23. , 73 . .

24. 24 . community-acquired .

25. 42 . . .

104 105

.3- (2,2). (2). . .

26. 21 . .

- . , (30)., , ( 31) .,.

27. 18 . .

28. 18 . . .

10 10

29. 18 . .

30. 28 - . CD-4 - 468. .

31. 25 - . . CD-4 - 84. .

32. 45 - . . CD-4 - 43. .

10 10

(33-35)., (3).M.avium- .

33. 75 . , - . . M. avium .

34. 48 . . M. kansasii .

35. 58 . . M.abscessus .

36. 52 . M. abscessus .

110 111

. . ( 3-3). .

, . .,, . , .

37. () 35 .

38. 28 .

39. 32 . . .

112 113

40. 56 . . .

. , .


2. DaleyCL.ThetypicallyatypicalradiographicpresentationoftuberculosisinadvancedHIVdisease.TubercleLungDis.15;:45-4.

3. ImJG,ItohH,HanMC.CTofpulmonarytuberculosis.SeminUltrasoundCTMR.15;1:420-434.

4. Jerajani-KamathH,AmbarasuA,MerchantSA,JankhariaB.High-resolutioncomputedtomographyfindingsinadultpulmonarytuberculosis:pictorialessay.CanAssocRadiolJ.1;50:33-342.

5. KhanMA,KornatDM,BachusB,WhitcomsME,BrodyJS,SniderGL.Clinicalandroent-genographicspectrumofpulmonarytuberculosisintheadults.AmJMed.1;2:31-3.

. KohDM,BellJR,BurkillGJ,PadleySP,HealyJC.Mycobacterialinfections:stillamillenniumbug-theimagingfeaturesmycobacterialinfections.ClinRadiol.2001;5:535-544.

. LopezFacalP.Technicasdeimageneneldiagnosticodelatuberculosispulmonaryyextra-pulmonar.In:CamineroLunaJA,ed.Tuberculosis.Madrid,Spain,GraficasLetraSA,12:-104.

. MarciniukDD,McNabBD,MartinWT,HoeppnerVP.Detectionofpulmonarytuberculosisinpatientswithanormalchestradiograph.Chest.1;115:445-452.

. McAdamsHP,ErasmusJ,WinterJA,Radiologicmanifestationsofpulmonarytuberculosis.RadiolClinNorthAm.15;33:55-.

10. PirrontiT,CecconiL,SallustioG,MeduriA,MacisG.Diagnosticimagingofpulmonarytuber-culosis.Rays.1;23:3-114.

11. RpttembergGT,ShawP.Radiologyofpulmonarytuberculosis.BrJHospMed.1;5:1-1.

. , 5 - . . . .

. . positive predictive value(PPV), . ,

114 115

-,,, , , , () .

(4).- .


2. ComstockGW,LivesayVT,WooppertSF.Theprognosisofappositivetuberculinreactioninchildhoodandadolescents.AmJEpidemiol.14;:131-13.

3. MenziesD.Interpretationofrepeatedtuberculintests.AmJRespirCritCareMed.1;15:15-21.

4. PesantiEL.Thenegativetuberculintest.AmJRespirCritCareMed.14;14:1-10.5. PinaJM,MartinA,GonzalesP,LopezJL,MiretP.Lapruebadelatuberculina.MedicinaInte-

gral.1;13:330-344.. AmericanThoracicSociety.Tuberculinskintest.Diagnosticstandardsandclassificationof

tuberculosisinadultsandchildren.AmJRespirCritcareMed.200;11:13-135.

,, ., . . .

(,,,,) , (,), . , (21,23).

(41, 42). , . . - .(, ..) .100%- .

41. .

11 11

42. . .

.

. ( 43), ( 44) (45).


2. CamineroJA,MedinaMV,RodriguezdeCastroF,CabreraP.Tuberculosisyotrasmicobacteri-osis.In:CamineroJA,FernadezFauL,eds.ManualdeNeumologiayCirugiaToracica.Madrid,Spain:EDIMPSA;1.

3. FargaV.Diagnosticodelatuberculosispulmonar.In:FargaV,ed.Tuberculosis.SantiagodeChile:Edit.Meditteraneo;12:103-11.

4. SauretJ,PeraltaE,LeonC,etal.Biopsiapulmonaryeneldiagnosticodelatuberculosis.MedClin.1;:215.

5. ThenorCP,HopewellPC,EliasD.etal.Humanimmunodeficiencyvirusinfectionintuberculo-sispatients.JInfectDis.10;12:-12.

43. . , .

11 11

44. . , .

45. . .

120 121

:

.20. , . .

:

1.: .2.::

-..-(

).3..

-,.

-.

. , -,.

,

.,,-(-).-,.

% ..2-3, . , . .

, , , . .10%-. ..

122 123

8 - -

10-15 ,.,,- . . , ,.

:1.()

,.25-30--.

2. , 2-3. , , .

3. ,., %- M. tuberculosis , M.tuberculosis- .,-.

4.,.,,, -, - .

5.( ), ,,-

,.

.,: i) ; ii) ;iii)- . , , .

. - .

, - . , , . :1---,.

- : , , , , ,,.

-

()-,25-30-.,.

- , ()

124 125

, - . ( 4); .-100010-15 200-4002-3 . , - , - Mycobacterium-.

., , ..

46. - . M. tuberculo-sis , .

25-30- , . -, - .

. ,.

.:. , . ,.,.

,.,. , - . - ( ) ., .

,. : 1) ; 2) (MB-Septi-Check);3).

,(2-3

12 12

). , , , .

:(Bactec40)-(,MGIT,ESP,MB/Bact).

(Bactec)

Bactec ,. , 14- ( ) 142- .412 0.4 .:1. (15-20).2. M.tuberculosis

.3. M. tuberculosis- 4-5 , 21-

42 - (,,, ,)3- . .

4. .

,:1. .2. ,,.3.

-.4. -.

14-,,.

. -, - ( ) . - , . -, - .

-

- , . , . ().,-,-.

:MGIT (M ); Bactec000 MB ; (ESP II-Myco; MB-BacT M ). , ( ).,2.

- (MB-Septi-Check)

, .20.

12 12

, . MB-Septi-Check ,, . , in vitro , M. tuberculosis.

- M. avium M. tuberculosis- . , -,.

.- , .,13,-.

,CD4+50/3--,-.

%- M. tuberculosis- M. tubercu-losis- , , -,-.

, , Bactec12B-NAP,,.

Bactec 12B- NAP

NAP(p-----) M. tuberculosis- . :Bactec12B,NAP- Bactec 12B. Bactec 12B NAP-M. tuberculosis-. .

,(,,,-,) . .

. - (TLC) .TLC-,.

, , . , , .

-

130 131

..

. , : ( ), ( ).

, -(..-0-140) (). .

M. tuberculosis, M. avium, M. intracellu-lare,M.kansasii, M. gordonae Gen-Probe,Syngene . .

, , ( ),.M.tuberculosis- , . .

-(PCR):1. ,

.

2. - ,-.

3. - ,, .PCR Mycobacterium- .

1S . PCR- . Mycobacterium-,.

.,,,-,-.,.-(10) . 2-3,., (10-).

- .( ) ( 0%).

10-.10- . 10- , ,

132 133

. : , rRNA ,,MGIT,MB,-,-,ESP , PCR-SSCP, MycoBact/Alert 3D, Inno-Lipa, ATP, PCR, ,.

, , . :(,,)21-2 ; ( 40 ) 3-5 -. .-,-..-40TB.,-(). .

M.tuberculosis-.

M. tuberculosis- ,.

M.tuberculosis-

:1. -:(0.01-

) ( ).-,-.

2. (1011),

- .2-3.

3. - . . 11 . , (5-10 ) (MIC) ..

M.tuberculosis-

(4-14), . , , ( ) -,-.:1. 12 . -

, . , . , , , .

2. (ESPII,MB-BacT,MGIT,Bactec000MB). , .

3. . M. tuberculosis- MICs , MIC . .

4. . 0 , M. tuberculosis MIC . -.

134 135

M. tuberculosis- in vitro

.:1. .

4 . .. ,..

2. (PhaB). M. tuberculo-sis M. smegmatis- . , (4 ), , ( ) . (5%) (5%).

3. .(24-30),,., .invitro(M.avium,M.marinum,M.fortuitum,M.gordonae).

,,..

M. tuberculosis

. 5%,100%.

( ) ..11-.

-

, : katG, inhA, ahpC,rpoB., - - - - -.,.

INNO-LipA-

rpoB 0%- INNO-LipA- . , : 1) M. tuberculo-sis- ; 2) rpoB %..,,0%.

13 13

().(1),.

-(>%)(>%).- .,(1-5%-),(50-0%)..

, , - -,.,-,-.

M.tuberculosis- .,-, M. tuberculosis-. (2-).

, . PCR , (LCR), Q ea, - -.:1);2),

M. tuberculosis ;3).

- - (>%)(>%).- , .,2000-3000 . AMTDT-2 ( ) - 3-5%, 5-% .PCR,LCR-.PCR-50-0%,.LCR.-LCR-53-2%,1-%.

, - ,M.tuberculosis- . , , (., ) . , %-M. tuber-culosis--,- . , (1-5% - ), ( 50-0%) . ,.

, , -.,.,(1-5%),.,.,

13 13

, , . - .,,.

, . .

,().

PCR . (4):1)-- ; 2) () ; 3) . (Taq ) . , (4).:1) ( ); 2) - ; 3) Taq.M.tuberculosis,M.avium,M. intracel-lulare.

PCR , .

47. PCR- .

LCR PCR- . , (4).LCxMTB--.

94

37

1

1Taq 74

140 141

, 2-10 . ,,.

48. LQ

(5).,.

-

AMTDT-2 ( M. tuberculosis ) - -(4).23S- , . ,, . (4 ), . AMTDT-3 . , .

1(23SrRNA). , --.

-

- --.1S-( ) : ,,.

..() , (,)

142 143

. - , ( ) .

49. /- - . RT=

100-1000

-

r

100, . .., .

, . , -(ELISA)., , ,. , .

ELISA- 100%., 3 - 50%-,().

,, - . , . .

, . (5-5%).(

144 145

..

., , .,() , ., . 20 .M.tuberculosis-.,,,-,-.

. IS110 .M. tuberculosis- IS110- 5-20 . : 1) ; 2) ; 3) ;4). .

,-,-.

. - .,,.

. : , M. tuberculosis- -, PCR -.(RFLP)., . : 1) ;2);3);4).

M. tuberculosis- IS110- (5-20 ) . - . ,,.IS110-.., . ,. , -, - .

14 14

, 5%- . ( .) -.

..

. . , .

,0/-(3.3/).,, , .,5000/-.50%- . , 1000 10- . .

. ,,(>5%) , , , ,-.

., , , .,,..40-45--10.

, -().,,.

(), .1.2-,,- ., .

-, . .

, (IAP) 1-.,-,-.

14 14

1. AmericanThoracicSociety.Diagnosticstandardsandclassificationoftuberculosisinadultsandchildren.AmJRespirCritCareMed.2000;11:13-135.

2. AusinaV,LuquinM.Diagnosticodelatuberculosisporserologia:situationactualperspectivasfuturas.ArchBronconeumol.10;2:1-11.

3. AusinaV,ManterolaJM,PadillaE.Nuevasperspectivaseneldiagnosticotoracia.In:SauretJ,ed.Tuberculosis,VisionActual.Madrid,Spain:AulaMedicaEdiciones;2001:23-5.

4. AusinaV.Actualidaddelatuberculosis.Unavisioncriticadelasnuevastecnicasdiagnosticas.EnfInfectMicrobiolClin.12;10:24-254.


. CamineroJA,MedinaMV,RodriguezdeCastroF,CabreraP.Tuberculosisotrasmicobacte-riosis.In:CamineroJA,FernandezFauL.ManualdeNeumologiaCirugiaToracia.Madrid,Spain:EDIMPSA;1.

. CamineroJA,RodriguezdeCastroF,CarrilloT,DiazF,RodriguezJC,CabreraP.DiagnosisofpleuraltuberculosisbydetectionofspecificIgGantiantigen0inserumandpleuralfluid.Respiration.13;0:5-2.

. CamineroJA.Diagnosticoserologicodelatuberculosisotrasmicobacteriosis.MedClin.10;4:1-15.

. CamineroJA.Tuberculosispleural.MedClin.10;4:34-3.10. CasalM.MicrobiologiaClinicadelasEnfermedadesporMicobacterias.Cordoba,Spain:

EdicionesUniversidaddeCordoba;11.11. CasalM.Sistemaradiometricosemiautomatizado(Bactec40)paramicrobiologiaclinicade

tuberculosismicobacteriosis.EnfInfectMicrobiolClin.1;5:4-51.12. GotoM,ShinichiO,OkuzumiK,KimuraS,ShimadaK.Evaluationofacridinium-esterlabelled

DNAprobesforidentificationofMycobacteriumtuberculosisandMycobacteriumintracellularecomplexinculture.JClinMicrobiol.11;2:243-24.

13. HermansPWM,SchuitemaARI,VanSoolingenD,etal.SpecificdetectionofMycobacteriumtuberculosiscomplexstrainsbypolymerasechainreaction.JClinMicrobiol.10;2:1204-1213.

14. JacksonK,SieversA,DwyerB.EffectofagitationofBactec13AbloodculturesonrecoveryofMycobacteriumaviumcomplex.JClinMicrobiol.11;2:101-103.

15. Kiehn,GoldJWM,BrannonP,TimbergerRJ,ArmstrongD.Mycobacteriumtuberculosisbacteremiadetectedbytheisolatorlysis-centrifugationbloodculturesystem.JClinMicrobiol.11;2:4-4.

1. LuquinM,AusinaV,LopezF,etal.Evaluationofpracticalchromatographicproceduresforidentificationofclinicalisolatesofmycobacteria.JClinMicrobiol.11;2:120-130.

1. MartinezJM,OcafiaK.Eficaciadiagnosticadelaadenosinadeaminasa(ADA)enlasserositistuberculosas.EnfInfectMicrobiolClin.1;:2-.

1. OcafiaJ,Martinez-VazquezJM,SeguraRM,FernandezdeSevillaT,CapdevilaJA.Adenosinedeaminaseinpleuralfluids.Testfordiagnosisoftuberculouspleuraleffusions.Chest.13;4:51-53.

1. PaoCC,YenTSB,YouJB,MaaJS,FissEM,ChangCH.DetectionandidentificationofMy-cobacteriumtuberculosisbyDNAamplification.JClinMicrobiol.10;2:1-10.

20. PetersonEM,LuR,FloydC,NakasoneA,FriedlyG,M.delaMazaL.DirectidentificationofMycobacteriumtuberculosis,MycobacteriumaviumsadMycobacteriumintracellularefromamplifiedprimaryculturesinBactecmediausingDNAprobes.JClinMicrobiol.1;2:1543-154.

21. Ross,RaiosK,JacksonK,etal.MolecularcloningofahighlyrepeatedDNAelementfromMycobacteriumtuberculosisanditsuseanepidemiologicaltool.JClinMicrobiol.12;30:42-4.

22. ThierryD,Brisson-NoelA,Levy-FrebaultV,NguyenS,GuesdonJL,GicquelB.Character-izationofaM.tuberculosisinsertionsequenceIS110,anditsapplicationindiagnosis.JClinMicrobiol.10;2:23-2.

23. VereaHR,MasaJF,DominguezL,PerezJ,MartinMT,FontanMD.Meaninganddiagnosisvalueofdeterminingthelysozymelevelofpleuralfluid.Chest.1:1:342-345.

9 -

: , . 150-10-2HRZ/4HR . 4%-.,2(E) . (R) .,. (H+RH+R+Z). 2HRZE/4HR2HRZE/HE.

(, , (Z), , ) , . , , , ..

, , . , ..

150 151

:50 , . . .. (140-).

. .143144 . , .()2-3. . (2-3).

144, - . - , 14 . , 112 151 ,, .

. .155- . .

- . ...

150-10-. . , .

.,() .

:,.

152 153

:

,., , (fallandrisephenomenon).,...,, () . 5 . .105-10. . .

5.

- 1105-- 110-- 1105-- 1105-- 1102-4- 1105-- 1103-

(,,) , .,

(+R-1013,H+R+E-101).

6.

- 110-- 110-- 1104-- 1104-- 1104-- 110-- 1104-

.

, - . .40, 110-140 . . :

//(emergent flora) 10- . , . , .() , .

154 155

..().

103-5., . . . (persistent bacterial flora) ...-5.4 50%-. ..

103-5. . . .

..(15-20,24).

. ..

2HRZ/4HR . () ((E))., -. 2-3 2HRZE/4H2R 2HRZE/4H3R3 . . - .

2HRZE/HE(- 2HRZE/HT) 2HRZE/4HR - .-.

15 15

H+R, H+R+Z, H+R+Z+E, H+E, H+T (TT) . , ..(bioavailability)-.

2HRZE/4H . (intermittentadministration)2HRZE/4HR. , .

. (H), (R) (Z) . . , , 4 . (1-2%-), . ().

2HRZ/4HR ..:( ), ( )().:

?

(,).., . , (5),.2 . ( 5). , ( ), 4%- 2 ..

, ?

. . . . . . ( , ..)

15 15

. .

2-3 ?

( ), 4%- 2 . ( 14-24).4. . 4 . . . 5.24 . , , (Eth) (T) . , .,,, . , ( ) . . .

( ) . ().. .. 4 . 3 ().

. , .( ). .

( )1-2 . .

? ?

2 , , ,4-2HRZE/4HR . . , .

10 11

,.., . .

. (2HRZE/HT) ( ). .. .

- 10 . . . .

() ?

. , .H+R,H+R+ZH+T-.H+R+Z+E(H+E) - .

-

. , , . . .-.

- .,-. ,. - - . .

?

, , 2 . . 4 .2HRZE/4AHR,2HRZE/4H2R22HRZE/4H3R3.-.

..

12 13

: ,

,,, . , ,. . ,.

(H),(R),(Z),(E)(S) , , , . . . . ( ),, , .,-11.

7. : , , , .

5/300/

15/ ,,

,

10/00/

10/00/

,,

, .

.

15-30/2

50/ ,

,,

.

15-20/ 50/

,,

15-20/1

25-30/1

,

,,

-,-

. :(Z):2HRE/HR(H):2REZ/10RE (R) : 2HEZ(S)/10HE(E):2HRZS/AHR

. . , , . .

. . ..

(R)1-24., .(Z).

14 15

(,, ..) ,2(2HRE/HR).

, 12, 2 (2REZ/10RE).

12 2(2HEZ/10HE). 2 (S).

2(2HRZS/4HR).

. (2HRZE/4HR).

..

, , , , , , , , , . .

,. .. .,,,, , , , .,. . 1/- , 1/ - .

, . .

...

8. .

,(1)25-50-

()

..

1 1

:,.

,

,

,

,()

3-

..

.

(--)

,

,

,(,45-)

,()

,

.

,()

().

, . , . , ,.

(2-3).,, -.

...

.

()..

./

1 1

-

, , ,..

:

1. . (, ),,individualvariability-.

2. . . .(),.

3. .,. . . ..

4. .. .

5. . 450- . ,.

. . .

. . .

. . ( ) . .

. . ..

10. -.- . .

(baseline) . . ,,,,,,,, ,,, , - . .

. (bimodal) . .

. , , , .

10 11

..

. , ..

, ( ) ,., , . . , .

. , , . .

, . ,2-4 . 2-4 , . 2-4 , . , .

, , , , , , , . , . - ,.

, . 3(1-2/), 2 ,. 1- ( 10) 2- ( 300 ),1.

:1.

.2.

.3.

.4. ,

.5.

.,. .

. .

12 13

. ,.

. 1/-, 1/ - ..

. , . .

10. .

11. ,.

., . -,(-).

. , , () . , ,, - . , , , , .

()450,, , , , (), , .

-12 . - () , .

,,,. ( ..) (,..).- :- .- .,

.

- . .

- . (additionphenomena), ( ), ().

, . , .,,,.

.

, ,. , , ,-.

14 15

, . -, (-).1.

.10( ) .,, ( ) . , , ,- ., , , , . , . , ().1.

-(M.avius- ), ( ),.,.-.

,. , .,.

10. .

,5%-,..,.,.

ACU-0-1%-,..

2%-,.

..

. .

.max1%-,AUC.

max2%-,AUC10%-..

.(,).12.

..

. .

max-30%-,AUC-3-5.()max-15%-.,.

maxAUC-.

-

,,.(-52%AUC).,,.

maxAUC-.

Cmax-. .

. ...

1 1

. ..

25%-. .

12.50%-.

AUC=areaunderthecurve,Cmax=maximumconcentration,Tmax=timetomaximumconcen-tration

()450 . , , , , (), ,.-12 . ,AUC-3%-,23%-.

- .CYP3A4 ( ) ,.,. , ,.2. : . ,,.

, , , , - , .

. , . . .

3TC, d4T dd .

.. .

(),..

, (, ,) . ,(myastheniagravis)-.

,.

., . ( , TSH).-. - ,

1 1

,(,12,,,).

.

. - .

.

- , , , , .,., , .

(E) (S) . () (H), (R)(2RES/10RE).

,,,,, ( ) . 2HRZ/4HR .

, . , , .

- ,,.

..(S),(Eth)...

,.,.

, , .

( (E) ) , ( (Z), - (PAS)) . :

(,,- ) , 2HES/10HE .

( ) ..2RES/10RE.

2RES/10RE.

, .

10 11

,,, , , ( ) . 2HRZ/4HR . . , 24 . , . 50/ . 50 /11...

11. 24 .

(/)

12 13

, .

, , - .

, , . , . ..

: .

. .

.. .

.

, . - .

, , ., .,.

:

- . , .

- . ,.

- .- .- ().- .

, . . ,(, , , ..), (, - , , ). , , .

: 1) , 2) , .

,, (), .

1. AmericanThoracicSociety.CentersforDiseaseControlandPrevention.Daignosticstandardsandclassificationoftuberculosisinadultsandchildren.AmJRespirCritCareMed.2000;11:131-135.

2. Thepromiseandrealityoffixeddosecombinationswithrifampin.AjointstatementoftheInter-nationalUnionAgaintsTuberculosisandLungDiseaseandtheTuberculosisProgrammeoftheWorldHealthOrganization.TubercleKungDis.14;5:10-11.

3. CamineroJA,MedinaMV,RodriguezdeCastroF,CabreraP.Tuberculosisyotrasmicobacte-riosis.In:CamineroJA,FernandezFauL.ManualdeNeumologiayCirugiaToracia.Madrid,Spain:EDIMPSA;1.

4. CamineroJA,PavonJM,RodriguezdeCastroF,etal.Evaluationofadirectlyobservedsixmonthsfullyintermittenttreatmentregimenfortuberculosisinpatientssuspectedofpoorcom-pliance.Thorax.1;51:1130-1133.

14 15

5. CoombsDL,GeiterLJ,OBrienRJ.TheUHPStuberculosisshort-coursechemotherapytrial21:effectivness,toxicity,andacceptability.Thereportoffinalresults.AnnInternMed.10;112:3-40.

. CrowleAJ.Inhibitionbystreptomycinoftuberclebacilliwithinculturedhumanmacrophages.AmRevRespirDis.14;130-3.

. CrowleAJ.Theeffectofethambutolontuberclebacilliwithinculturedhumanmacrophages.AmRevRespirDis.15;132-42.

. EtzcornET,LillisPK,McAllisterCK.TuberculosisinKorea.Therelationshipbetweenpriortherapyanddrugresistance.Chest.1;1;0:24-250.

. FoxW,EllardGA,MitchisonDA.StudiesonthetreatmentoftuberculosisundertakenbytheBritishMedicalResearchCouncilTuberculosisUnit,14-1,withrelevantsubsequentpubli-cations.IntJTubecrLungDis.1;3(suppl2):S231-S2.

10. GirlingDJ.Efectosadversosdelosmedicamentosantituberculosos.BolUnionIntTuberc.14;5:153-14.

11. GrossetJ.Bacteriologicalbasisforshort-coursechemotherapyfortuberculosis.ClinChestMed.10;231-242.

12. GrzybowskiS,EnarsonDA.Eldestinodeloscasosdetuberculosispulmonarsometidosadif-ferentesformasdetratamiento.BolUnionIntTuberc.1;53:-1.

13. HinshawHC,FeldmanWH.Streptomycinintreatmentofclinicaltuberculosis:apreliminaryreport.ProcStaffMeetMayoClin.145;20:313-31.

14. InternationalUnionAgainstTuberculosisandLungDisease.Antituberculosisregimensofchemotherapy.RecommendationsfromtheCommitteeonTreatmentoftheInternationalUnionAgainstTuberculosisandLungDisease.BullIntUnionTubercLungDis.1;3:0-4.

15. JindaniA,AberVR,EdwardsEA,MitchisonDA.Theearlybactericidalactivityofdrugsinpatientswithpulmonarytuberculosis.AmRevRespirDis.10;121-3.

1. MitchisonDA,NunnAJ.Influenceofinitialdrugresistanceastheresponsetoshortcourseche-motherapyofpulmonarytuberculosis.AmRevRespirDis.1;133:423-430.

1. MitchisonDA.Basicmechanismsofchemotherapy.Chest.1;(suppl):1-1.1. MitchisonDA.Drugresistanceinmycobacteria.BMJ.14;40:4-0.1. MouldingT,DuttAK,ReichmanLB.Fixeddosecombinationsofantituberculousmedications

topreventdrugresistance.AnnInternMed.15;122:51-54.20. OrganizacionMundialdelaSalud.TratamientodelaTuberculosis.GuiaparaProgramasNacio-

nales.Segunda,ed.Ginebra:OMS;1.21. PeloquinCA.Drugsfortuberculosis.In:PiscielliSC,RodvoldKA,eds.DrugInteractionsin

InfectipusDiseases.Totowa,NewJersey:HumanaPress;2000:10-120.22. SchatzA,BuhieE,WaksmanSA.Streptomycin,asubstanceexhibitingantibioticactivityagainst

gram-positiveandgram-negativebacteria.ProcSocExperBiolMed.144;55:-.23. SingaporeTuberculosisService/BritishMedicalResearchCouncil.Assessmentofadailycom-

binedpreparationofizoniazid,rifampin,andpositivepulmonarytuberculosis.AmRevRespirDis.11;143:0-12.

24. SmallPM,FujiwaraPI.ManagementoftuberculosisintheNitedStates.NEnglJMed.2001;345:1-200.

25. TusetM.Interaccionesmedicamentosasentrelosantiretroviralesylosantituberculosos,EnfEmerg.2000;3:14-13.

10 -

;,.- . , - .

:,,,..

, .., - .- .13; - ,.

-,- , . , - -,.,--.

, - - -

1 1

(2HRZES/1HRZE/5H3R3E3) . , . , () - 0%- ,(.,) . --.

, - - -:3(Z,Kn,Eth,)/15(Z,Eth,). - .

,-,-.

.,.,-. , - .,, . - : ,.

- , - , - - . , - , - , .

- , .

- : , ,

- ,, , . -.-,.

, . . . .,, ,., , .

-,,.

, . . 12-24 ., .

1 1

. ,.., -.

, . , . , . .

. . - (2HRZE/4HR) . - (2HRZE/HE) . , , .,.,.

. , in vitro , 50% - .-,,. . .

() . . , .. . (). .

,,.,.

- . - , . .

-..,,,. ,.

10 11

,,(). , .

, , (30-0) ( 50) , . ( ) , -.

3 ( ), .,invitroinvivo ,. ...

- .- ..-.

-,- 4-5 . - .

-

- 10 ..1-24.12.-, - . M. tuberculosos- 13 .-3., .

12-10- . 3.1-24. 12 .-,, - , . , , -.

12. -

1. ,,-.-.

2. -.

3. .

4. (.,

12 13

)3.5. .. .. -,: -*: -. : -1 -12. .10.

.

*, . .

:

:

1

2

3

4

5

10

11

12

H

R

Z

E

S

Kn

Ak

Cp

Ofl

Cip

Eth

Pt

PA

S

C

s

C

fz

*

*

*

*

H:

R:

Z:

E

:

S:

Kn

:

A

k:

C

p:

O

fl:

Cip

:

E

th:

P

t:

PA

S:

Cs:

C

fz:

*

:

;

:

50

.

.

-

.

,

.

14 15

-,12-:1. ,

. . ., , .

2. - . ,. ..,-.

3. ..

4. ..

5. .

- 13- ; - , . 13- 13 . ,,-(, , , , )., ..-,.,-.

13.

1.2.3.4.5.....-10.11.-12. - - - - -13.

-

-:,,,, , - , ( ).- , , , . - - . - .

14--,,,, . :1. 150- .

, ..- (- ).

1 1

.2.

. -.

3. ,,. -11 . ,- , 2-3 .

4. ...

5. (). - . - .

. ,-.

14. - , ,

15-30/1

YIII,

,,BUN

-

15-30/1

YIII,

,,BUN

-

15-30/1

,

+

150/12

,

10-20/1

,,

+

BUN=;=;=;SGPT=;=-

:

. . , , , .

-, - ( )- . , , . .

M.tuberculosos-,. . : .

M. tuberculosos-

in vitro . ( , , ,FCE22250,GCP21,R--1),,,,

1 1

. (, ,, , ), (, , ), , -, .

, ,,.

() (MICs) ,., - 0%, 100%..

,,450-..

(24 ) ( 25-50 ) . , . 00 - . ,,., 00 . - - 00 1200 . . , FCE22250,GCP21,R--1 . .

-.-. . -.

- .-:,invi-tro,-,,..

( .) -( .) MICs - . , ., . ,,,-.

, , in vitro , MICs,., .

200 201

. . (,U-10040,)invitro. in vivo . .,, . - . , .

invitroinvivoM.tuberculosos-.PA-24,().,PA-24-, , . PA-24 . PA-24 . , .-M.tuberculosos-PA-24.,.-..

. Q()-.

, , , , ,, , , , --D- , , .

, : , - ( ), -.

,- . , , , - .

. (- - )(0.2nm-2-3nm). - .,.5.,. , ,,.

-

-

202 203

. . , ,-.:-.

, - . , , -., , . , - - .

- - : -, -

- -.

, -(2HRZES/1HRZE/5H3R3E3)--. , . - -0%-., , .--.

, -, - :3(, , , ) / 15

(, , ) - .-.

- , - .

-.

, , , . , , , . - . , ( ) . , , , . , ,- - .- . -5000-10.000100.000.

- - -

.,10-15%

204 205

.,10.000 1500- - .,50-500.,-.- (., , , , ) .().(0%),.

- . , . , - . - 5000-000 ,10-20.,-(), 250-350. 50-100.

, - - - . - - (2HRZES/1HRZE/5H3R3E3), US$30.. (-)50%-. , 1-2%- (.,). , -.

- - - : ?

- - - -, - - . .,?-?

: , - , - -. .--.,-.-., , --., . - 1 . :,,() ( )3,, 15 . -10005000-000.

-,, - 1-24 -.

20 20

-

- . , - - .,,,-. - -. . ,,-.

- . , , - (2HRZES/1HRZE/5H3R3E3), - - . , ,(15%).-..

- , , - . - ( - ), ( - -) --.,,,-.,-, - - . -,-1

.- ., , .

,-,-.

1. AmericanThoracicSociety.Treatmentoftuberculosisandtuberculosisinfectioninadultsandchildren.AmJRespirCritCareMed.14;14:135-134.

2. BritishTuberculosisAssociation.Ethionamide,cycloserineandpyrazinamideinthetreatmentofdrugresistanttuberculosis.Tubercle.14;44:15-214.

3. CamineroJA.Resistenciaprimariaafarmacosantituberculosos.MedClin.1;3:30-3.4. CamineroJA.Tratamientodelaenfermedadtuberculosa.Pautasterapeuticas.In:CamineroJA.

Tuberculosis.Madrid,Spain:GraficasLetra,SA;12:15-12.5. CasalM.Promisingnewdrugsinthetreatmentoftuberculosisandmycobacteriosis.JChemoth-

er.1;1:3-45.. CroftonJ,ChauletP,MaherD.DirectricesparaelTratamientodelaTuberculosisFarmacorre-

sistente.Ginebra:OrganizationMundialdelaSalud;1.. CroftonJ.Failureinthetreatmentofpulmonarytuberculosis:potentialcausesandtheiravoid-

ance.BullIntUnionTuberc.10;55:3-.. EastAfrican/BritishMedicalResearchCouncilRetreatmentInvestigation.Streptomycinplus

PASpluspyrazinamideintheretreatmentofpulmonarytuberculosisinEastAfrica.Tubercle.11;52:11-1.

. FargaV.Tuberculosis.Segunda,ed.SantiagodeChile:EditorialMediterraneo;12.10. FujiwaraPI,SimonePM,MunsiffSS.Thetreatmentoftuberculosis.In:ReichmanLB,Her-

shfieldES,eds.Tuberculosis:AComprehensiveInternationalApproach.2nded.Revisedandexpanded.NewYork,NewYork:MarcelDekker;2000.

11. GobleM,IsemanMD,MadsenLA,WaiteD,AckersonL,HorsburghCR.Treatmentof11patientswithpulmonarytuberculosisresistanttoisoniazidandrifampicin.NEnglJMed.13;32:532-53.

12. GonzalezMontanerLJ,PalmeroDJ.TuberculosisMulti-Resistente.BuenosAires,Argentina:LaboratorioHoechstMarionRoussel;1.

13. HongKongChestService/BritishMedicalResearchCouncil.Acontrolledstudyofrifabutinandanuncontrolledstudyofofloxacinintheretreatmentofpatientswithpulmonarytuberculosisresistanttoisoniazid,streptomycinandrifampicin.TubercleLungDis.12;3:5-.

14. InternationalUnionAgainstTuberculosisandLungDisease.Antituberculosisregimensofchemotherapy.RecommendationsfromtheCommitteeonTreatmentoftheInternationalUnionAgainstTuberculosisandLungDisease.BullIntUnionTubercLungDis.1;3:0-4.

15. IsemanMD.Treatmentofmultidrug-resistanttuberculosis.NEnglJMed.13;32:4-1.1. JointTuberculosisCommitteeoftheBritishThoracicSociety.Controlandpreventionoftuber-

culosisintheUnitedKingdom:CodeofPractice14.Thorax.14;4:113-1200.1. MarchP,TurellJ.Re-tratamientodeltuberculosocronicocondrogasdereserva.Resultados

tardiosenobservacionescontroladasdeunoacuatroafios.EnfTorax.10;5:103-111.1. MarchP.Resistenciasprimariassecundariasalasdrogasantituberculosas.Revistalbys.

10;2:13-14.

20 20

1. MitchisonDA.Basicmechanismsofchemotherapy.Chest.1;(suppl):1-1.20. OrganizationMundialdelaSalud.TratamientodelaTuberculosis.GuiaparaProgramasNacio-

nales.Segundaedition.Ginebra:OMS;1.21. OrtegaA.Retratamientosentuberculosis.RevClinEsp.1;10:2-24.22. PeloquinCA.Drugsfortuberculosis.In:PiscitelliSC,RodvoldKA,eds.DrugInteractionsin

InfectiousDiseases.Totowa,NewJersey:HumanaPress;2000:10-120.23. PilheuJA,deSalvoMC,GneccoV,GiannattasioJ,HoffmanM.Recaidasdelatuberculosis

pulmonar.Valordelinterrogatorioparalaselectiondelesquematerapeuticoadecuado.ArchBroncoceumol.12;1:11-123.

24. PretetS,LebeauA,ParrotR,TruffotC,GrossetJ,DinhXuanAT.Combinedchemotherapyincludingrifabutinforrifampicinandisoniazidresistantpulmonarytuberculosis.EurRespirJ.12;5:0-4.

25. ReyR.Conductaterapeuticaenlatuberculosispulmonar:enfermosenretratamiento.ArchBronconeumol.1;15:-1.

2. SommerAR,BraceAA.Ethionamide,cycloserineandpyrazinamideusedsuccessfullyinthetreatmentofchronicpulmonarytuberculosis.Tubercle.12;42:345.

2. StewartSM,CroftonJW.Theclinicalsignificanceoflowdegreeofdrugresistanceinpulmo-narytuberculosis.AmRevRespirDis.14;:11-2.

2. SullivanAE,SullivanEA,KreiswirthBN,etal.Emergenceoffluoroquinoloneresistanttubercu-losisinNewYorkCity.Lancet.15;345:114-1150.

2. Truffot-PernotC,JiB,GrossetJ.Activitiesofpefloxacinandofloxacinagainstmycobacteria:invitroandmouseexperiments.Tubercle.11;2:5-4.

30. TusetM.Interaccionesmedicamentosasentrelosantirretroviraleslosantituberculosos.En-fEmerg.2000;3:14-13.

31. InternationalUnionAgainstTuberculosis.Acomparisonofregimensofethionamide,pyrazin-amideandcycloserineinretreatmentofpatientswithpulmonarytuberculosis.BulllntUnionTuberc.1;42:-5.

32. VillarinoE.Nuevosfarmacoscontralatuberculosis.EnfEmerg.2000;3:13-14.

11 - M. tuberculosos-

.()- , .,,, . :1. -.2. ,

().3. .4. .5. .. .

, . 50 .. () .

,M. tuberculosos . (katG) (),.,., ,-., , .

210 211

M.tuberculosos . , , M. tuberculosos- . . M. tuberculo-sos-,.,M.tubercu-losos-.

. . -. (., ) . , (., ). .

. , .

M.tuberculosos- . ( 5) -

:105-10;10-10.105-10,102-104. . , .10-10,103-105().,,., , . ,.,(, ),., ., .,- :1014,101,-1010-12.

, ,.,-. , . .(). , .().()(). ,

212 213

, (). . 1;.

, ().

. , .

, , (1-2000 ).(-14.4%,-10.2%),(.%),(5.3%),(4%),(3.%),(2.%),(2.5%).(13.3%),(11.3%).

,.-(0%,0.2%,0.3%,0.3%,0.5%,0.%,0.%,0.%,1%,1.1%,

214 215

23.0,15.13-.- 354%.

,.:1)(:0%,:0.2%,:0.3%,:0.3%,:0.5%,:0.%,:0.%,:0.%,:1%,:1.1%,:

21 21

. , , . . .-., , -.

,...-,.., .

,(10%-). ,10- 10 - (10%).,,, ,150-10-,,.

M. tuberculosos

. katG,(,) , . , -, - .,,.

, 0-%- rpoB ., , , . ,.-,.

, . katG . 22-4%- . , katG. ,,

21 21

., katG - , , . . , Pneumocystis carinii M. avium - . -.

(inhA,ahpC,kasA)M.tuberculosos-,,. 10- ., ahpC , kasA 50%-,katG.inhA.

,- . ,.katG- , katG- ahpC-.

- , , . ,- , .-:1.-.2..3..

4..5....

. - 10, 50, 100.

, - .,-, (10.000 ) . - -,- - . . , - - . , - - . - . -10,50,100 . - .:1. -,

. - .,,- , , , , ,, , , (, , , , .)-.

2. .. .

220 221

3. .- (,) , - ( ,, ), ( : , , -, ) , .

4. . , .1-..,,,, ., ,.+ , + +.

5. . , .-.-, . ,, , , . .,- .-,,.,, .

. . .

, . , . , , ; .,10 ,. , ,.

1. AusinaV.Tuberculosismultirresistente.Puntualizacionesreflexionessobreuntemapolemicodecandenteactualidad.MedClin(Bare).1;10:15-1.

2. CamineroJA.Origenpresentefuturodelasresistenciasentuberculosis.ArchBronconeumol.2001;3:35-42.

3. CamineroJA.Resistenciaprimariaafarmacosantituberculosos.MedClin(Bare).1;3:30-3.

4. CentersforDiseaseControl.Nationalactionplantocombatmultidrug-resistanttuberculosis.MMWRMorbMortalWklyRep.12;41(RR-11):5-.

5. CohnML,OdaU,KovitzC,MiddlebrookG.Studiesonisoniazidandtuberclebacilli:theisola-tionofisoniazid-resistantmutantsinvitro.AmRevTuberc.154;0:45-45.

. EspinalM,LaszloA,SimonsenL,etal.Globaltrendsinresistancetoantituberculosisdrugs.NEnglJMed.2001;344:124-1302.

. FoxW,EllardGA,MitchisonDA.StudiesonthetreatmentoftuberculosisundertakenbytheBritishMedicalResearchCouncilTuberculosisUnit,14-1,withrelevantsubsequentpubli-cations.IntJTubercLungDis.1;3(suppl2):S231-S2.

. MitchisonDA.Drugresistanceinmycobacteria.BMJ.14;40:4-0.. MorrisS,BaiG,SuffysP,Portillo-GomezL,FairchokM,RouseD.Molecularmechanisms

ofmultipledrugresistanceinclinicalisolatesofMycobacteriumtuberculosis.JInfectDis.15;11:54-0.

10. MusserJ.Antimicrobialagentresistanceinmycobacteria:moleculargeneticinsights.ClinMicrobRev.15;:4-514.

11. TelentiA,HonoreN,BernasconiC,etal.Genotypicassessmentofisoniazidandrifampinresis-tanceinMycobacteriumtuberculosis:ablindstudyatreferencelaboratorylevel.JClinMicro-biol.1;35:1-23.

12. ZhangY,HeymB,AllenB,YoungD,ColeS.Thecatalase-peroxidasegeneandisoniazidresis-tanceofMycobacteriumtuberculosis.Nature.12:35:51-53.

222 223

12 -

,.,-., . , .

, , ().:1),;2);3);4) ; 5) -.

:1) ; 2) , ;3)., , - . , ,,.

, ., .

. . . , . . , - ,, . , . .

(3-), , ...12. , , ( ),. ,,.

-

3 4- , , ,

224 225

. XVIII - , ,..M.tuberculosos- , ( 20 ). , 4-5%- .,, .

, . , , , . XX . ,., , - .

150- .,.

,, .

-

,.-.,., ( ) . .

, , .-.()10 . , - . ; .,,:,. , .

22 22

, ,,.

. - - ., , ,( 10-14%) . ..100,000()1-.--100,000-20-,-100,000-20-.,--1-1%-.40-50100,00010-. , .

, , ,.,15,() .

. , , .,50%-.

, , , . 150- : 1) ; 2) .

-. , 25 , . 2-3 , .

150-..,150- . ,15,,, . , ().

, -

22 22

. , , ,. , 50%- . , ( ) , (.. ,). , (,),., .

10- (), () . - , ,. . , 14().5:1);2) ;3);4) ; 5) .

10-- .- , , .5(,,,, ) , .

.,.,- - .---., - .

-14 , - . -5():

1. . , ..,,.

230 231

2. . . . , . ,. : 1 ( ),2(, 1- , M. tuberculosos ), 3 ( , )..

3. - - , (2 ) . .

4. . . - .., . , ,.

5. - . . :- .- ( 3,

).- .-

:

.

5,5%- , - 0%-(2000),. - 3-4 . .

, . - , 40-50 - ,.., 30-40 .,.

:1);2) ;3) . , , - ().,,,,.

232 233

: 1) ; 2) ; 3) . , .

,,-().:1. .100%-

5-0%().-50%.

2. . . .,,.

3. . ().., 20, . - .

4. . () ( ), .

5. .(,),() . (.. ) ()..

- ,(-) . -, - , - 5%- , %- . .

, . , , , ,(2-3,) . .

-,..,100,000100- . -.( ) ( ) . . .

, , .

234 235

- . M. tuberculosos- .:1) (- ); 2) , . ( ) ,,,.

, . . ,.,,- 20-0%., . -, - . . , .

- .,.,,,.

-,.,(3,12).:

1. . , . 4 , .2,..- .

2. .. , ( ).

3. .1.

4. . , .().

5. . . , .

. . 4(-5)...

0%-,%-. , (-) . -()5%-,%-.

- -

23 23

; () (.. , ) . - , , . .,.

,,.

, 5%- ,%- - . ().

, .2-3/().,. . (1-%),- .

- .10-15-, , , - - . .(,), - . ().

, 3 : 1) , ; 2) , , ( ); 3) - , . - .

, ,,. (2-3 ) ..

-,- , .,- ( ) ,., .

23 23

(.. ) (.. 100.000 100- ) ., ( , ) . , , . - , ,- . ,, , , , , , .

- ,().. .

, . - .

,,,. , (

) . . 13- , ,.13--:1);2); 3) . , ().

13-, ( ,), . . () . - .

, .

. , ,.,,.

240 241

, ,,,.

,

M. tuberculosos- .,., . :

- .

- ,-,-,.

- .

- ,.

4-,. ( , , , , ). M. tu-berculosos- . , .,.

M. tuberculosos- ,., . .,,-(),.,..

., , . , () . ,,. . . , ,.,,,.

(-),(, ), .

,

M. tuberculosos , , . , ,.

242 243

, .

-, - , . ,.,,.

, . (, , )%.;% . . , (,),,..

.,., 50%- . , . . , .

.,( ) , . , .%.10US$-.,.-, - .

M. tuberculo-sos- , .,.,, , . , .

, , ( ). -., .

244 245

1. AlcaideJ,AltetMN,SallerasLI.VacunaBCG.In:SallerasLL,ed.VacunacionesPreventivas.PrincipiosAplicaciones.Chapter21.Barcelona,Spain:EdMasson,SA;1:405-444.

2. CamineroJA.^Eslaquimioprofilaxisunabuenaestrategiaparaelcontroldelatuberculosis.MedClin.2001;l1:223-22.

3. CamineroJA.Medidasbasicasparaelcontroldelatuberculosisenunacomunidad.MedClin(Bare).14;102:-3.

4. EnarsonDA.PrincipiosdelosprogramasdecontroldelatuberculosisencolaboracionconlaUICTER.BolUnionIntTubercEn/Resp.11;:215-220.

5. Essentialcomponentsofatuberculosispreventionandcontrolprogram.RecommendationsoftheAdvisoryCouncilfortheEliminationofTuberculosis.MMWRMorbMortalWklyRep.15;44:1-1.

. FargaV.Tuberculosis.Programasdecontroldelatuberculosis.In:FargaV,ed.Segundaedition.SantiagodeChile:EditorialMediterraneo;12:24-23.

. GolditzGA,BrewerTF,BerkeyCS,etal.EfficacyofBCGvaccineinthepreventionoftubercu-losis.Meta-analysisofthepublishedliterature.JAMA.14;21:-02.

. GrzybowskiS,EnarsonDA.Eldestinodeloscasosdetuberculosispulmonarsometidosadife-rentesformasdetratamiento.BolUnInternTuberc.1;53:-1.

. MurrayCJ,DeJongheE,ChumHJ,NyanguluDS,SalomaoA,StybloK.Costeffectivenessofchemotherapyforpulmonarytuberculosisinthreesub-SaharanAfricancountries.Lancet.11;33:1305-130.

10. StybloK.Recentadvancesinepidemiologicalresearchintuberculosis.AdvTubercRes.10;20:l-3.

11. WorldHealthOrganization.WHOExpertCommitteeonTuberculosis.NinthReport.Geneva,Switzerland:WHO;14.

12. WorldHealthOrganization.WHOTuberculosisProgramme:FrameworkForEffectiveTuber-culosisControl.WHO/TB/4.1.Geneva,Switzerland:WHO:14.

13 -

. 2:. . . .

- , , . 12- , , , .-, 12- ., .

. ..

,

24 24

. .

() ,.

-,.-:1)M.tuberculosis--; 2) , ; 3) . .-,:1) ( );2)(-,,);3),.

- - . ,,, - ---- 5- ;-(-.), - 10-15; -.

, . .,150- . . .,.

10 . , , 5 . - .

- . .-,, - ,,(2000), . ,- .-:; ;

24 24

- .1-,,.

-- ( ) .

-.,- , ,-.-.

-

- : .

-

, ,.15-3., ( ,5- , , ) (35-,,).

15. -

1. .

2. (-).

3. .

,() ( 1) , (15).:M.tuberculosis - ; ,; . 3 ,.2.

16. -

1. M.tuberculosis.2. (),.3. ,.

( 4, 1) , ( ). - . .

M.tuberculosis

M. tuberculosis -

250 251

. ,,. , . ,-.

,

150, 10- - , . , . ,-.

,,

- 2.30 - .().,-.

( 4, 1) .

, - . ++ 3 .. , () , . ,. .

, 15- , 1 -(5) . M.tuberculosis- ; . . ,.

. .3-4

252 253

.;..

(4,1).,.,(-);;() , ; , . 2000 4 , . , .

--

. - . , , .-

. (1):1);2) ; 3) - .

17. - -

1.2.3.-

- ( 1) , .(5%)(30%) (0%).

18. - . .

*

(%)

(%)

(%)

5 0 30 1 100

10 0 30 2 50

10 0 0 5 20

30 0 30 14

30 0 50 12

30 0 0 1 5

-...

(100- ) . .(30%) (50%) , (0%),

254 255

(10-) . - : M. tuberculosis- , ( ) .(-), . -.-M.tuberculosis- ; ,..

.

.- .,- M. tuberculosis- .,. M. tuberculosis , , . ., ().2-3(..

) .,, . , .

.,,-3 -10 . .:5/,10/,300-().

. 4- ( 1), ( 1) .

3( 1) - . ,.,1%-5-10,5%-50. . ,

25 25

.,..

- .- , , . , ,.-.,-,. -..

, . , ( ) . , , , ,. ,

.

,M.tuberculosis-. . , ,,,, (windowperiod).-. - ,.

,,,-,,.,.

-

,,.100% . , (,), .. , 5-0%- . , - - . ,,:

25 25

- , -. , ( 0% ) ,, . , ( ) , . ( ) -,5-.M.tuberculosis.

- , -. , , . ,,. . , , ., - ( )10-15.

- , , , - . , . , , .

.-., , . , .

1. AdvisoryCouncilontheEliminationofTuberculosis.Tuberculosiseliminationrevisited:obsta-cles,opportunities,andarenewedcommitment.MMWRMorbMortalWklyRep.1;4(RR-):1-13.

2. AmericanThoracicSociety.CentersforDiseaseControlandPrevention.Targetedtuberculintestingandtreatmentoflatenttuberculosisinfection.AmJRespirCritCareMed.2000;11:S221-S24.

3. CamineroJA.^Eslaquimioprofilaxisunabuenaestrategiaparaelcontroldelatuberculosis.MedClin.2001;l1:223-22.

4. ComstockGW,FerebeeSH,HammesLM.Acontrolledtrialofcommunity-wideisoniazidprophylaxisinAlaska.AmRevRespirDis.1;5:35-43.

5. CowieRL.Short-coursechemoprophylaxiswithrifampin,isoniazidandpyrazinamidefortu-berculosisevaluatedingoldminerswithchronicsilicosis:adouble-blindplacebocontrolledtrial.TubercleLungDis.1;:23-243.

. FerebeeSH,MountFW.Tuberculosismorbidityinacontrolledtrialoftheprophylacticuseofisoniazidamonghouseholdcontacts.AmRevRespirDis.12;5:40-521.

. FerebeeSH.Controlledchemoprophylaxistrialsintuberculosis.Ageneralreview.AdvTubercRes.10;1:2-10.

. GordinFM,ChaissonRE,MattsJP,etal.Aninternational,randomizedtrialofrifampinandpyrazinamideversusisoniazidforpreventionoftuberculosisinHIV-1infectedpersons.JAMA.2000;23:1445-1450.

. InternationalUnionagainstTuberculosis.CommitteeonProphylaxis.Efficacyofvariousdura-tionsofisoniazidpreventivetherapyfortuberculosis:fiveyearsoffollow-upintheIUATLDtrial.BullWorldHealthOrgan.12;0:555-54.

10. JointTuberculosisCommitteeoftheBritishThoracicSociety.Controlandpreventionoftuber-culosisintheUnitedKingdom:codeofpractice14.Thorax.14;4:113-1200.

11. PapeJW,JeanSS,HoJL,HafherA,JohnsonWDJr.Effectofisoniazidprophylaxisoninci-denceofactivetuberculosisandprogressionofHIVinfection.Lancet.13;342:2-22.

12. RiederHL.EpidemiologicBasisofTuberculosisControl.1sted.Paris,France:InternationalUnionAgainstTuberculosisandLungDisease;1.

13. WhalenCC,JohnsonJL,OkweraA,etal.AtrialofthreeregimenstopreventtuberculosisinUgandanadultsinfectedwiththehumanimmunodeficiencyvirus.NEnglJMed.1;33:01-0.

, 13 230 11 M. bovis-

20 21

. ()4:()1132,1331,(Glaxo)10,12.

,; , - . , M. tuberculosis- .

- .0-0%-.. (5-%), 50% - . - .

M.tuberculosis- ; , . , , . , ,.

,., .

10 .

, M. bovis- . - ().,,, . , 10 , . 13 230 . -.

121 , 124--25-... II .14 , , , . 14 355, . 10-1,2000 . 1 - 2000 .

-

,-.150-, . . ,,,,

22 23

, , . 15 -. : , (10-034 ), 1343. , , .

,.30-. , seed-lot.seed-lot, - seed.seed-lot-12..

- -,,physical,. . .

,

10 . -:- ()1132- 1331- (Glaxo) 10; 150- 1331

(Merieux,

Evans-).- 12, ,

.

: Moreau (), Montreal (,Connaught),(),Tice().

--105104520-(CFU).,.

, , 14 - , - . 12 .

-1/200.1-,,.deltoid-10.2-3,, ; 3-4,-12,,,.

, ,.:- -

. .

- -.

- . , , .-.

24 25

- - . ,.- ..

- (5- ). .,M.tuberculosis-,-,Ag30-32kD,.

- ( ) .

- : , ,..

- . , .

- . .

-

. 0% , ..:

-

. , ,

(,),. , ..

. .,., . (510-4520).

.

. , , ,.

( 1). 200%. 31% .

2 2

14-1514.100,13.200 . 5 20,(1%%).,2 (, 150-155) 5%,1115.000 ( , 1-11):0-141%,140%. .

., 5% . , 20.14 %-3%,5%.

19.

()

0-20

-11 2

1-1 1-20 2

5-1 20 -5

, >5 14 14

12-24 5

14-15 15

-14 20 4

()

20 1.5

() 15 0

-() 2-13 .

()

15 1

-

() () . , . ..

- - ( 20, 21) 4%, 0% . ., 25% 0-1 , . .

20. -

/()

(%)

-

()

1

2 2

() 0-30 5(23-5)

-()

20 21

- . , 51%,- 50% . 4%, - 52% . , , ,-.

, , ..22- . , . . , -.

22.

1. : - - -2. : - - - - -3. -: -- - - -

4. 5. ,. M.tuberculosis-

. .

:

- M.tuberculosis-.- .- , ,

.-

.-

.- .-

.- ,

.,5%, .

- .

5- . , . 5- .

22 23

,5,10..

, .:- . 23- . - . .

. , . .

- : (15-1) (1-11) . 1- 5.5 . 3 3- .25,1. . 1-5.5;13..1-3.4;1-0.. ,.

- , . ().

23.

1. : 1.1,, 1.22. -;; 2.1 2.2 2.3-: 2.4 2.5,() 2., 2. 2. 2./,,

3. -;;4. 4.1(,) 4.2() 4.3 4.4, 4.5,

:

:,,3 , , . ,, , ,,..3 .

3- , : ?- ? , . ,

24 25

, .

, , 1%- . ( 2 ) , . , . 0% ().

;0.2-1% . , , . , -,,.

, 0.1%- . ,

,,100%.. , . , .

, , ,.,1%-.

--, .- . , .

,. ( , ) . ,:

2 2

1. 5,100.0005.

2. 5-5101-.

3. 0.1% .

1. AlcaideJ,AltetMN,SallerasLI.VacunaBCG.In:SallerasLL,ed.VacunacionesPreventivas.PrincipiosAplicaciones.Chapter21.Barcelon

A Tuberculosis Guide for Specialist Physicians

Documents

Transcript of A Tuberculosis Guide for Specialist Physicians